Prime Medicine, Inc.
Business
Prime Medicine is a biotechnology company developing genetic medicines using Prime Editing, a gene-editing technology designed to provide durable, potentially curative treatment for diseases driven by genetic alterations. The company is advancing a pipeline of wholly owned in vivo programs targeting liver diseases, including Wilson Disease and alpha-1 antitrypsin deficiency, as well as cystic fibrosis, alongside ex vivo programs with Bristol-Myers Squibb and a program in chronic granulomatous disease. Prime Medicine operates through modular platform architecture to enable efficient development across multiple indications, with focus on liver-directed diseases and partnerships to expand Prime Editing applications.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 5 | 3 | 0 | 0 | 0 | |
| Research and development | 161 | 155 | 148 | 87 | 71 | |
| General and administrative | 52 | 50 | 43 | 30 | 14 | |
| Total operating expenses | 213 | 205 | 205 | 117 | 84 | |
| Loss from operations | −208 | −202 | −205 | −117 | −84 | |
| Interest income | 4 | 4 | 3 | — | — | |
| Accretion (amortization) of investments | 2 | 4 | 6 | — | — | |
| Change in fair value of short-term investment related party | 432,000 | −485,000 | −2 | −8 | — | |
| Other income, net | 148,000 | 41,000 | 274,000 | 2 | 12,000 | |
| Total other income, net | 7 | 7 | 6 | −6 | −81 | |
| Net loss attributable to common stockholders, basic | −201 | −196 | −198 | −142 | −184 | |
| Net loss attributable to common stockholders, diluted | −201 | −196 | −198 | −142 | −184 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | −1.35 | −1.65 | −2.18 | −4.19 | −14.19 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | −1.35 | −1.65 | −2.18 | −4.19 | −14.19 | |
| Weighted-average common shares outstanding, diluted (in shares) | 149 | 119 | 91 | 34 | 13 | |
| Weighted-average common shares outstanding, basic (in shares) | 149 | 119 | 91 | 34 | 13 | |
| Net loss | −201 | −196 | −198 | −122 | −165 | |
| Change in unrealized loss on investments, net of tax | 81,000 | 16,000 | 369,000 | −357,000 | −27,000 | |
| Comprehensive loss | −201 | −196 | −198 | −122 | −165 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 63 | 182 | 42 | 188 | 185 | |
| Prepaid expenses | 3 | 7 | 19 | 2 | — | |
| Other current assets | 674,000 | 15 | 2 | 246,000 | — | |
| Total current assets | 181 | 212 | 143 | 297 | 271 | |
| Property and equipment, net | 21 | 24 | 23 | 19 | 5 | |
| Operating lease right-of-use assets | 126 | 47 | 14 | 30 | 11 | |
| Restricted cash | 14 | 14 | 13 | 13 | 13 | |
| Other assets | 1 | 0 | 779,000 | 2 | 2 | |
| Total assets | 343 | 298 | 194 | 360 | 302 | |
| Accounts payable | 9 | 11 | 20 | 4 | 1 | |
| Accrued expenses and other current liabilities | 13 | 16 | 14 | 11 | 37 | |
| Deferred revenue related party | 8 | 7 | 0 | — | — | |
| Operating lease liability | 8 | 4 | 9 | 12 | 7 | |
| Total current liabilities | 37 | 38 | 56 | 27 | 58 | |
| Deferred revenue, net of current related party | 58 | 63 | 0 | — | — | |
| Operating lease liability, net of current | 108 | 37 | 4 | 17 | 3 | |
| Research and development funding liability | 18 | 6 | 0 | — | — | |
| Total liabilities | 222 | 144 | 61 | 44 | 62 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Common stock, par value of $0.00001 per share; 775,000,000 shares authorized; 180,514,014 and 131,160,842 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 2,000 | 2,000 | 2,000 | 0 | |
| Additional paid-in capital | 1,009 | 840 | 624 | 610 | 15 | |
| Accumulated other comprehensive income | 82,000 | 1,000 | −15,000 | −384,000 | −27,000 | |
| Accumulated deficit | −888 | −687 | −491 | −293 | −171 | |
| Total stockholders equity | 121 | 153 | 133 | 316 | −156 | |
| Total liabilities and stockholders equity | 343 | 298 | 194 | 360 | 302 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 29 | 26 | 14 | 6 | 2 | |
| Non cash lease expense | 10 | 12 | 13 | 10 | 4 | |
| Depreciation expense | 7 | 6 | 5 | 2 | 600,000 | |
| Change in fair value of short-term investment related party | −432,000 | 484,000 | 2 | 8 | — | |
| Amortization of premiums and discount on short-term investments | −2 | −3 | −3 | — | — | |
| Prepaid expenses and other current assets | 5 | −16 | −9 | −2 | −885,000 | |
| Accounts payable | 996,000 | −5 | 9 | 2 | 1 | |
| Accrued expenses and other current liabilities | −1 | 2 | 2 | −26 | 35 | |
| Accrued settlement payment related party | 0 | −14 | 14 | 0 | — | |
| Deferred revenue related party | −4 | 70 | 0 | — | — | |
| Lease liability | −5 | −6 | −12 | −10 | −4 | |
| Net cash used in operating activities | −163 | −123 | −165 | −132 | −34 | |
| Maturities of investments | 96 | 204 | 133 | 93 | 13 | |
| Sales of investments related party | 5 | 0 | — | — | — | |
| Purchases of investments | −205 | −129 | −105 | −123 | −82 | |
| Purchases of property and equipment | −5 | −7 | −9 | −16 | −4 | |
| Return (payment) of security deposit | 0 | 1 | −170,000 | — | — | |
| Net cash (used in) provided by investing activities | −109 | 68 | 19 | −47 | −74 | |
| Proceeds from follow-on offering, net of issuance costs | 138 | 132 | 0 | — | — | |
| Proceeds from research and development funding liability | 12 | 6 | 0 | — | — | |
| Net proceeds from stock option exercises | 781,000 | 103,000 | 655,000 | 219,000 | 0 | |
| Proceeds from ESPP offerings | 341,000 | 837,000 | 0 | — | — | |
| Proceeds from issuance of common stock under the BMS Securities Purchase Agreement related party | 0 | 38 | 0 | — | — | |
| Net cash provided by financing activities | 152 | 196 | 655,000 | 181 | 269 | |
| Net change in cash, cash equivalents, and restricted cash | −120 | 141 | −146 | 3 | 162 | |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 84 | 45 | 3 | 29 | 12 | |
| Decrease in right-of-use assets due to lease termination | 3 | 0 | 6 | 0 | — | |
| Increase in right-of-use assets upon settlement with landlord | 11 | 0 | — | — | — | |
| Purchases of property and equipment included in accounts payable and accrued expenses | 114,000 | 1 | 575,000 | 969,000 | 754,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Prime Medicine, Inc.'s CIK number?
Prime Medicine, Inc.'s SEC CIK number is 0001894562 (1894562). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Prime Medicine, Inc.'s SEC filings?
All of Prime Medicine, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Prime Medicine, Inc. last report earnings?
Prime Medicine, Inc. (PRME) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-031719). This is Prime Medicine, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Prime Medicine, Inc.'s most recent earnings 8-K?
Prime Medicine, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-031719. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Prime Medicine, Inc.'s latest earnings 8-K →
Look up any company's CIK number →